A Phase 2, Open-Label, Multicenter, Tumor-agnostic Study of MK-1084 as Monotherapy and in Combination with Cetuximab, in Participants with KRAS G12C-Mutant, Advanced Solid Tumors (KANDLELIT-014)
Norway, Spain, Sweden, Italy, Denmark, France, Poland, Germany, Greece
Condition studied
Neoplasm malignant with KRAS G12C mutation
Investigational medicinal product(s)
CETUXIMABMK-1084MK-1084MK-1084MK-1084
Eligibility
Age group
65+ years, 18-64 years
Sex
Female, Male
Primary endpoint
Objective Response Rate (ORR), Number of Participants Who Experience One or More Adverse Events (AEs), Number of Participants Who Discontinue Study Intervention Due to an AE
Endpoint detail
Overall Survival (OS), Duration of Response (DOR), Progression-free Survival (PFS)
Official registry record
This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time on our Cookie Policy page. See also our Privacy Policy.